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Abstract 
 
Background 
The South African Healthcare landscape has changed dramatically over the last two 
years with the implementation of mandatory substitution, single exit pricing and 
prescribed minimum benefits.  The private market for medicines is becoming more 
competitive and commoditized.  Between July 2004 and June 2005 there were 119 
generic registrations at the Medicines Control Council. In the US and Canada research 
has been conducted on the change in prescribing behaviour induced through incentive 
based formularies and the impact of generic medicines on healthcare costs.  This 
research protocol aims to build on this body of knowledge by analysing sales trends 
within a therapeutic class after the launch of a generic molecule in the same class. 
This research investigates how the introduction of generics may impact the growth of 
the innovator molecules and subsequent generics.  The therapeutic class Acid Pump 
Inhibitors has been selected.   
 
Method 
Unit sales of Proton Pump Inhibitors are drawn monthly from sales in the total private 
market.  They are then grouped by molecule and comparisons are drawn between the 
originator and it’s generic to determine association.  This is also done at the aggregate 
level where the originators form one group and generics the second group.  Each 
aggregate group’s average growth in the therapeutic class is then calculated to 
determine the aggregate group’s evolution index.   
 
Data Analysis 
Data is analysed through descriptive and interpretative statistics.  The descriptive 
statistics establish a relationship between generisized molecules and the non 
generisized molecules.  A t-test for two independent means is used to test the 
hypothesis that the non generisized molecules in the therapeutic class have a 
significant higher growth. 
 
Conclusion 
The results demonstrate that the number of units sold of the generisized molecules 
increase as they become more affordable, however contrary to intuition the number of 
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units sold of the non generisized molecules also increase.  The research shows that 
there is a statistically significant greater growth, albeit on a smaller base, of the non 
generisized molecules over generisized molecules. 
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Abbreviations 
 
IMS  Internal medical sales 
MAT Moving annual totals 
EI  Evolution index 
MCC  Medicines Control Council 
PPI  Proton pump inhibitors 
SEP   Single exit pricing 
API   Active pharmaceutical ingredient 
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Glossary 
 
The Act: 
Medicines and related substances control Act 101 of 1965 as amended. 
 
Active pharmaceutical ingredient ( API ): 
Is a substance or mixture of substances intended to be used in the manufacture of a 
medicine and that becomes an active ingredient of the medicine.  API’s are intended 
to cause pharmacological activity or other direct effects in the diagnosis, cure, 
mitigation, treatment or prevention of disease or to affect the structure or function of 
the body. 
 
Aggregate data: 
When referring to aggregate data it is implied that the data is not molecule specific. 
Data is grouped into two broad aggregates, generisized molecules and non generisized 
molecules. 
 
Dispensing fee 
Is the amount, which is as yet to be decided by MCC, that will be deemed to be an 
appropriate dispensing fee to be charged by a pharmacist or by a person licensed in 
terms of section 22C (1) (a) of the Act as remuneration for dispensing a medicine. 
 
Evolution index  ( EI ): 
The Evolution index for a product is a statistic calculated by Internal Medical Sales 
(IMS) per local market. It is used internationally as a measure of growth of a product 
in relation to the growth of the class to which the product belongs. 
  
Product growth for territory = x% 
Therapeutic class growth for the territory = y% 
 
(100 + x%) / (100 + y%) %  = EI% 
 
EI indicates that your product is performing better (>100) or worse (<100) than the 
therapeutic class as a whole. 
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First to market generics: 
A first to market generic is a molecule that is approved and registered for sale by the 
relevant medicines regulatory authority of a country once the patent on the originator 
molecule has expired. 
 
Generics:  
Generics or interchangeable multi-source medicines means medicines that contain the 
same active substances which are identical in strength or concentration, dosage form 
and route of administration and meet the same or comparable standards, which 
comply with the requirements for therapeutic equivalence as prescribed in the 
regulations to the Act. 
 
Internal Medical Sales (IMS): 
Internal Medical Sales Health is an organization that collates and compiles sales and 
product data related to sales across four areas, namely, dispensing doctors, private 
hospitals, non-retail pharmacy outlets and retail pharmacy outlets. 
 
Logistics fee 
Logistic or distribution fee, the amount which is as yet to be decided by the Medicines 
Control Council (MCC), to be charged by wholesalers or distributors or any other 
person for the distribution Scheduled medicines. 
 
Mandatory substitution 
A pharmacist is obliged in terms of the Act to dispense a generic of a branded 
medicine unless expressly forbidden by the patient to do so.  
 
A pharmacist shall not sell an interchangeable multi-source medicine-  
 
(a) if the person prescribing the medicine has written in his or her 
own hand on the prescription the words 'no substitution' next to 
the item prescribed;  
 
(b) if the retail price of the interchangeable multi-source medicine 
is higher than that of the prescribed medicine; or 
 
(c) where the product has been declared not substitutable by the 
Council. 
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Me-too generics: 
Me-too generics are generic medicine that have been launched after the first to market 
generic medicine and are also approved and registered by the relevant medicines 
regulatory authority of a country. 
 
Medicines Control Council (MCC): 
The Medicines Control Council (MCC) is a statutory body that was established in 
terms of the Medicines and Related Substances Control Act, 101 of 1965, to oversee 
the regulation of medicines in South Africa.  It is appointed by the Minister of Health 
and its main purpose is to safeguard and protect the public through ensuring that all 
medicines that are sold and used in South Africa are safe, therapeutically effective and 
consistently meet acceptable standards of quality. 
 
Molecule specific data: 
Molecule specific data is all the data that is relevant to one molecule e.g. Omeprazole. 
 
Moving Annual Totals (MAT): 
Moving annual totals are the totals achieved for a period of twelve months.  For every 
new month added to the total the oldest month is dropped off.  This ensures that at any 
point the total reflects twelve months only. MAT is used to smooth out inter month 
variations.  These variations are attributable to stock in the supply chain.  
 
Originator molecule: 
An originator molecule is a molecule that has been developed by an individual or an 
organization through a process of original research and development.  This molecule 
has to be proven to be efficacious and safe in humans before it can be registered by 
the relevant medicines regulatory authority of the country and only then can it be 
taken to market.  Safety and efficacy is proven by way of rigorous clinical trials. The 
cost to develop an originator molecule can be upwards of USD 800m and often takes 
seven to eight years.  Once the molecule is registered it enjoys a period of patent 
protection. 
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Prescribed minimum benefits: 
Prescribed minimum benefits is a basic benefit package covering twenty five chronic 
illness on which compulsory medical cover will be provided by medical schemes. 
 
Private market 
The private market is defined as the sum total of medicines prescribed to those 
individuals that are serviced by private hospitals, retail pharmacies, non retail 
pharmacies and dispensing doctors that do not obtain their stock through a process of 
government tenders and distribution. 
 
Public market 
The public market encompasses all the medicines that are procured by a process of 
government tenders and prescribed in public hospitals, public clinics and by health 
practitioners who have obtained stock from the government distribution centers. 
 
Proton pump inhibitors (PPI)  
Proton pump inhibitors are a group of drugs whose main action is the pronounced and 
long-lasting reduction of gastric acid production.  They are the most potent inhibitors 
of acid secretion available today.  These drugs are among the most widely selling 
drugs in the world as a result of their outstanding efficacy and safety.  Structurally, all 
of these drugs are substituted benzimidazoles. 
 
Single Exit Pricing (SEP) 
The single exit price is the price which is published by the manufacturers and the only 
price at which a manufacturer can sell medicines and Scheduled substances to any 
person other than the State. No pharmacist or person licensed in terms of section 22C 
(1) (a) of the Medicines and Related substances control act 101 of 1965 as amended or 
wholesaler or distributor can sell a medicine at a price higher than the single exit 
price.  
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1 Introduction 
 
 
1.1 What is a generic medicine? 
 
A pharmaceutical product derives its efficacy and safety from the chemical active it 
contains, also known as its active pharmaceutical ingredient (API) 1. This chemical 
active or molecule is the result of many years of research and expense. The intellectual 
property on this molecule is closely guarded and protected by registering various 
patents on the product.  Significant international harmonization of a patent’s term 
across national laws was provided in the 1990s by the implementation of the World 
Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPs Agreement). Article 33 of the TRIPs Agreement provided that 
the term of protection available for patents shall not end before the expiration of a 
period of twenty years counted from the filing date. This ensures that the molecule can 
be commercialized profitably before attracting competition. 
 
Once the life of this patent, has expired the molecule if still commercially viable may 
be generisized.  Generisized means that the molecule is now manufactured by 
companies other than the originator without infringing on any patents. To be classed as 
a generic of the originator the manufacturer of the generic has to prove to the relevant 
authority that the generic is therapeutically equivalent to the originator.  
 
The requirements for therapeutic equivalence2 are:  
 
(1) A medicine is considered therapeutically equivalent to another medicine if 
both medicines:-  
• are pharmaceutically equivalent, i.e., contain the same amount of  active 
substances in the same dosage form, meet the same or comparable standards 
and are intended to be administered by the same route; and 
• after administration in the same molar dose, their effects with respect to both 
efficacy and safety are essentially the same. 
 
(2) Therapeutic equivalence is determined from comparative bioavailability, 
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pharmacodynamic, clinical or in vitro studies which meet the requirements and 
accepted criteria for bioequivalence as determined by the Council. 
 
 
1.2 Market trends of generic medicines in South Africa 
 
The South African medicines market is divided into two exclusive markets, the 
State and the Private sector. IMS (Internal Medical Sales) is the premium source 
of sales and market share data in the private market in South Africa. IMS data 
measures the units and value of stock sold monthly (Annexure 1 - IMS data sheet 
sample).  
 
The Medicines Control Council (MCC) is the only regulatory body in South 
Africa that can register a medicine for sale in South Africa. From July 2004 to 
June 2005, 119 registrations for generic medicines were approved by the 
Medicines Control Council. This rate of approvals is expected to continue as there 
are many announcements of new registrations on the MCC website 
(www.mccza.com). The launch of a generic medicine creates competition and 
reduces the cost of a particular molecule. 
 
While intuitively one would suspect that the introduction of new generics, single 
exit pricing (SEP)  and mandatory substitution would reduce the cost of 
medicines, Rand sales data on the total private market  (IMS) suggests that market 
expenditure on medicines has grown by 10%3 from 2005 to 2006. This could 
possibly be explained by the implementation of prescribed minimum benefits4 
whereby the healthcare insurer is now compelled to provide cover for 270 
conditions which are treated in hospital as well as 25 chronic diseases and hence 
provides more medicines cover. However, spending in the insured market on 
pharmaceuticals has decreased from R8.7b in 2003 to R8b in 20044.  
 
These are conflicting trends, whereby legislation is moving towards making 
medicines more affordable,  but spend on medicines in the private market is on 
the increase taking into account a population increase.  The other conflicting trend 
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is that more chronic conditions are now reimbursed but spend on medicines by the 
medical schemes has decreased. 
 
This makes the interpretation of market trends in the South African generic 
market more challenging.  One trend that the investing community generally 
agrees on is that the growth of generics is estimated at 27% per annum till 20095. 
 
1.3 South African medical schemes data on pharmaceutical spend 
 
South Africa’s demographics can be constructed as a three layered pyramid. With 
the top layer comprising of 7 million privately insured lives, the private market. A 
middle layer of 14 million lives comprising of employed but uninsured 
individuals, the emerging market. The bottom layer comprising of 24 million lives 
of unemployed or informally employed and uninsured individuals that avail 
exclusively of public healthcare. 
 
Data presented in the Medical Schemes Council Annual Report 2004, the private 
market, states that monies spent on pharmaceuticals through medical scheme 
reimbursements has decreased from R8.7b to R8b while the number of members 
has remained constant on 7million. 
 
Insurance coverage for drugs reduces the sensitivity of the consumer to price 
differences and enhances the ability of pharmaceutical companies to set their 
prices well above the cost of production and distribution6. Healthcare payers have 
several mechanisms to implement price controls. These are capping of prices of 
new drugs, reference pricing drugs to same drugs in other similar countries, item 
by item pricing that takes into account degree of innovation in country of origin, 
imposing capitated reimbursement schemes to providers, rate of return profit 
regulations and reference pricing lists.  
 
It appears from medical scheme reference pricing lists7, that the manufacturer’s 
list price has remained static from 2003 to 2006 and reimbursement of medicines 
is set at list price plus a dispensing fee.  The Department of Health had put a 
moratorium on price increases for the last three years. 
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Medical schemes data has been relatively static in terms of pharmaceutical price 
and spend4 between 2004 and 2005.  Therefore, the impact by medical schemes on 
the growth of medicines in the private market through pricing pressure and 
number of members has been limited. 
 
 
1.4 Change in spending patterns on generic medicines in South Africa  
 
Generics accounted for almost 50% of the market in volume and for a third of 
sales value5 in 2005 this is up from 30% of the market in volume and 20% of 
sales value in 2004. 
 
Pre SEP, which was implemented on 1 August 2004, the dispensing of a 
particular brand of generic medicine was largely determined by the margin a 
retailer would make as long as it was approved by the MCC. Prior to mandatory 
substitution the retailer could dispense the branded product even if there were 
much cheaper generic versions of the medicines available. 
 
Post SEP the incentive to prescribe a particular brand of a generic is no longer 
determined by the margin a retailer can make. Following mandatory substitution 
the justification to prescribe a branded medicine when there is a generic available 
has become much more onerous. 
 
What this has led to is the tightening of what is reimbursed and at what level by 
the medical schemes. Medical schemes now have a legal justification to approve 
only the cheaper generic and at the same time to substitute away from the more 
expensive branded product. 
 
Therefore, it appears that although private market sales are increasing by 10% it is 
not through more monies being spent by medical schemes but by the individual 
out of his or her pocket.  
 
This “out of pocket expenditure” phenomenon may be created when the funds 
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available to an individual from a medical scheme are not able to meet the 
expenditure on medicines. Alternatively, the medicines that are being prescribed 
are either partially or wholly not covered by the medical scheme. This would 
imply that, in the context of generic medication, only generic medicines are 
approved by the medical scheme and non generics are allocated to the member’s 
personal account.  
 
This raises the question as to whether a non  generic would ever be prescribed 
over a generisized molecule. The Medicines and Related Substances Control Act 
101 of 1965 (The Act) as amended8 makes provision for the prescription of a non 
generic under certain conditions. These conditions include that the doctor 
prescribing a generisized medicine has to hand write on the script that the 
medicine is not substitutable. Depending on medical scheme rules the scheme 
then may either reimburse the patient or ask the patient to pay the difference 
between the cost of the branded medicine and the generic medicine.  
 
A study of IMS data, however, shows that originator products are still prescribed. 
They decline in sales sharply once a generic is launched, though they do not 
disappear completely. Therefore, there is still a market for the originator medicine 
even if it is generisized, even though the originator molecule may have a 
statistically insignificant different efficacy or safety profile to the generic 
molecule as a result of the way its API was synthesized. Alternatively, the 
“branded” product may be perceived as the “gold standard” although this may be 
difficult to justify scientifically.  
 
The change of spending patterns has two dimensions. Firstly there has been a 
change towards generics bought about by legislation. Secondly there has been a 
change in who is spending money in the private market. The  Council of Medical 
Schemes Report 2006 suggests that there was a benefit payout on medicines of  
Rand 7.2 million in 2005 and a drop of  11.6% (inflation adjusted) between 2002 
and 2005. With private market expenditure on medicines growing it appears that 
the insured individual is now spending more on medication compared to the 
medical scheme.  
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1.5 International financial trends of generics 
 
Data from adults included in the American Medical Expenditure Panel Survey 
1997-2000 indicates that there would have been a saving of approximately USD 
8.8b or 11% if all possible originator drugs would have been substituted with their 
generic equivalent9. The important conclusion from this survey is that generic 
substitution would only affect a modest percentage of drug expenditure (11%); 
however, it could result in a substantial absolute saving. In other words the impact 
of generic substitution would affect a modest proportion of the total drug bill. 
 
One would expect that the introduction of me-too generics would erode the price 
of the first to market generic. The Canadian experience10 indicates that first to 
market generics accounted for 53% of total expenditure and 75% of total use in 
1996 and 27% of expenditure and 54% of total use in 2003. On the other hand 
me-too generics accounted for 63% of expenditure and 44% of use by 2003. The 
average cost of me-too generic brands per day of treatment was four times that of 
first to market generics. An interpretation of the above statistics would suggest 
that initially generics help to bring the price of medicines down.  Subsequent 
generics bring the cost of treatment up again. This result is note worthy as one 
would believe more generics help to commoditized the market and bring the price 
of medicines down.  
 
Me-too generics are a profitable business.   The first generic has to often defend 
patent infringement challenges by the manufacturer of the originator and 
resistance by the doctor and patient.  Me-too generics on the other hand enter an 
established market. Me-too generics can also have higher margins than first to 
market generics as they can enjoy the benefits of more modern automated 
manufacturing equipment such as high speed tablet presses, integrated processes 
such as integrated fluid bed dryers for drying of powders verses oven drying and 
the commoditization of the active pharmaceutical ingredient often from low cost 
countries like India and China contributing with world class API synthesis which 
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was historically the domain of costlier first world European manufacturers.  
 
Therefore, most trends point to an increase in the use of generic molecules.  This 
research report questions this intuitive reasoning by investigating a particular 
therapeutic class of drugs.  The therapeutic class chosen is the proton pump 
inhibitors. 
 
 
1.6 Proton pump inhibitors 
 
1.6.1 Structure 
 
 
 
1.6.2 Clinical Use 
 
Schedule 2 and 4 medicines in terms of  the Medicines Control Act No. 101 of 
1965. 
These drugs are utilized in the treatment of many conditions such as11: 
• dyspepsia 
• peptic ulcer disease (PUD) 
• Zollinger-Ellison syndrome 
• Gastroesophageal reflux disease (GORD/GERD) 
• Prevention of stress gastritis 
• Gastrinomas and other conditions that cause hypersecretion of acid 
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1.6.3 Mechanism of action 
 
Proton pump inhibitors act by irreversibly blocking the hydrogen/potassium 
adenosine triphosphatase enzyme system11 (the H+/K+ ATPase, or more 
commonly the gastric proton pump) of the gastric parietal cell.  The proton 
pump is the terminal stage in gastric acid secretion, being directly responsible 
for secreting H+ ions into the gastric lumen, making it an ideal target for 
inhibiting acid secretion.  Targeting the terminal-step in acid production, as well 
as the irreversible nature of the inhibition, result in a class of drugs that is 
significantly more effective than H2 antagonists and reduces gastric acid 
secretion by up to 95%11. 
 
The lack of the acid in the stomach will aid in the healing of duodenal ulcers, 
and reduces the pain from indigestion and heartburn, which is caused by excess 
stomach acid. 
 
The proton pump inhibitors are administered in an inactive form12.  The inactive 
form is neutrally charged (lipophilic) and readily crosses cell membranes into 
intracellular compartments (like the parietal cell canaliculus) that have acidic 
environments.  In an acid environment, the inactive drug is protonated and 
rearranges into its active form.  As described above, the active form will 
covalently and irreversibly bind to the gastric proton pump, deactivating it. 
 
 
1.6.4 The pharmacokinetics of Proton Pump Inhibitors 
 
Generally, the absorption12 of proton pump inhibitors is unaffected by co-
administration with food.  The rate of omeprazole, lansoprazole and 
esomeprazole absorption is decreased and delayed by food.  These 
pharmacokinetic effects, however, reportedly have no significant impact on 
efficacy. 
 
The elimination half-life of proton pump inhibitors ranges from 0.5–2 hours, 
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however, the effect of a single dose on acid secretion usually persists up to 2–3 
days.  This is because of accumulation of the drug in parietal cell canaliculi and 
the irreversible nature of proton pump inhibition. 
 
1.6.5 Clinically used proton pump inhibitors: 
 
• Omeprazole (brand names: Losec, Omiloc ,Omez, Sandoz Omeprazole, 
Adco-Omeprazole, Altosec, Nozer)  
• Lansoprazole (brand names: Lanzor, Lanzoloc, Adco-Roznal, Aspen 
Lanzoprazole)  
• Esomeprazole (brand name: Nexium) 
• Pantoprazole (brand names: Pantoloc, Controloc, Topozole)  
• Rabeprazole (brand name: Pariet)  
 
1.6.6 Adverse effects 
 
Proton pump inhibitors are generally well tolerated, and the incidence of 
adverse effects12 is relatively uncommon.  The range and occurrence of adverse 
effects are similar for all of the proton pump inhibitors, though they have been 
reported more frequently with omeprazole12.  This may be due to its longer 
availability and hence clinical experience.  Common adverse effects include: 
headache, nausea, diarrhoea, abdominal pain, fatigue, dizziness.  
 
Infrequent adverse effects include: rash, itch, flatulence, constipation. 
Decreased cyanocobalamin (vitamin B12) absorption may occur with long-term 
use12. 
 
Recently it has been observed13 that gastric acid suppression, using H2-receptor 
antagonists and proton pump inhibitors, is associated with an increased risk of 
community-acquired pneumonia.  It is suspected that acid suppression results in 
insufficient elimination of pathogenic organisms.  It has, therefore, been 
suggested13 that patients at higher risk of pneumonia should only be prescribed 
proton pump inhibitors at lower doses and only when necessary.  
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1.7 Reasons why Proton Pump Inhibitors were used in the Research 
 
• The class is well populated with various molecules (5) of which one is an 
isomer. 
• Large multinationals as well as local companies market the molecules in 
the class. 
• The class has a large market value of approximately R320m and market 
share is well defended by the manufacturers through advertising and 
promotions.  
• There have been numerous generics launched in this class in the time 
period of the study. 
• Therapeutic and generic substitution is prevalent in the class, i.e. there is 
movement within the class. 
• The class is prescribed at both the surgeon and physician level. 
• Proton pump inhibitors are prescribed for both acute and chronic 
conditions. 
• Two molecules in the class, namely Pariet and Nexium have no generic 
equivalents in the time frame of the research which makes for a good 
comparison of 2004, 2005 and 2006. 
 
 
1.8 Evolution Index 
 
The rationale for using the evolution index (EI) of a medicine as a means to 
determine growth was the following: 
 
• Growth in the population does not affect the evolution index as it is based 
on a rate of growth. 
• It is a mathematical way to determine if the medicine is growing at a faster 
rate or slower rate compared to the rest of the market. Where an EI is 100 
the medicine is growing at the same rate as the market i.e. it is not gaining 
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market share. If an EI is less then 100 then the medicines is losing market 
share and vice versa. 
• The EI of a medicine in a therapeutic class is independent of whether the 
total market is growing or declining for the therapeutic class in relation to 
other classes. 
• The EI is an independent stochastic variable. 
 
 
1.9 Limitations of the study 
 
1.9.1 New legislation 
 
One of the confounding variables that might influence this study is the rapid 
change over the last twenty four months of the South African pharmaceutical 
landscape.  This change has been driven by legislation8 and the regulations set 
out by the Council of Medical Schemes4 to align the healthcare industry with 
national healthcare policy.  
 
1.9.2 Single exit price 
 
Historically medicines were marked up by 50% off the manufacturer’s list price. 
The profit a retailer would make would be the difference between a discount or 
rebate off a manufacturer’s list price and the marked up price.  As competition 
increased retailers started discounting this markup.  With the advent of SEP, 
manufacturers stopped rebates and discounts on the list price and the retailer’s 
markup was replaced by a dispensing fee. 
 
The introduction of the single exit price has had a significant impact.  Single 
exit price is the drug price that pharmaceutical companies set and what the 
retailer has to charge by law.  It cannot be influenced by bonusing, rebates and 
discounts. The strategy was designed to have saved between 50%-70% of drug 
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related costs; however, in reality the figure is closer to 14%.     
 
1.9.3 Dispensing fee 
 
The mechanism of the as yet not finalized dispensing fee being charged by 
pharmacists is based on a flat fee for medicines.  As per the current Department 
of Health legislation, where SEP is less than or equal to R100, 26% of the SEP 
is added to the price of the medicine as a dispensing fee.  For medicines with an 
SEP greater then R100, a flat dispensing fee of R26 is charged.  The incentive to 
prescribe more expensive medication is therefore still there as prescribing a 
medicine greater then R100 guarantees the R26 dispensing fee. 
 
1.9.4 Logistics fee 
 
The logistic fee which is as yet also undecided has put the future of wholesalers 
into uncertainty as they are unsure whether they will have viable businesses if 
this fee is set too low.  However, at this point the logistics fee could be used as a 
mechanism by retailers to extract discounts from manufacturers to promote a 
particular brand of medicine.  Retailers could hide discounts received as a 
logistics fee paid to a distributor with whom they have an affiliation. 
 
 
1.9.5 Reimbursement of generic medicines 
 
Another factor that may have influenced the price of generics is that insurance 
coverage for generic drugs is set at 100% of the SEP which ensures that 
reimbursements rates for drugs can be set well above the cost of production and 
distribution6.  This results in the desensitization of the individual to the price of 
the generic drug.  The individual’s concern now only extends to whether the 
medicine fully reimbursed by the medical scheme and not to any value for 
money concept. 
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1.9.6 Other variables 
 
Other confounding variables such as changed adherence to medication 14, 15 and 
formularies 16, 17 are not dealt with in this report. 
 
 
2 Aims and objectives of the research 
 
 
2.1 Statement of the problem 
 
The launch of a generic molecule in a therapeutic class results in the originator 
molecule loosing market share as cheaper versions of the molecule become 
available.  Medical schemes and legislation oblige doctors and pharmacists to 
prescribe away from these generisized originator molecules to the cheaper 
generics.  This report considers the sales impact on the non generisized molecules 
when a generic is launched in the same therapeutic class.   
 
 
2.2 Aim 
 
This research compares the unit growth as measured by the evolution index of 
generisized and non generisized molecules in a therapeutic class as more generics 
are launched in the class.  It analyses whether the launch of generics leads to a 
significant unit growth of non generic molecules in the same therapeutic class. 
 
 
2.3 Objectives 
 
1) Collect moving annual totals (MAT) data on PPI between August 2003 
and May 2006 (34 months) to determine the trends in sales volume 
between the various PPI.  
 
2) Calculate the evolution index (EI) of the various molecules of the 
therapeutic class to determine growth of each product in the therapeutic 
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class.  
 
3) Plot the trends in EI between the generisized molecules and non 
generisized molecules to determine whether generic substitution may be 
prevalent. 
 
4) Group EI’s into two categories namely generisized molecules and non 
generisized molecules in the therapeutic class proton pump inhibitors so as 
to be able to compare the EI’s of the two groups.  
 
5) Calculate the average EI per month of each group so as to be able to 
compare the average EI of the two groups by means of a t –test to 
determine if the average growth of products in one group is significantly 
different from the average growth of products in the other group. 
 
6) To interpret the result obtained in objective 5 with reference to market 
trends, medical scheme data, spending patterns and legislation. 
 
 
 
3 Methodology 
 
A list of generic and originator products was identified for the PPI class. These 
included the following molecules; Omeprazole, Lansoprazole, Pantoprazole, 
Rabeprazole and Esomeprazole ( S-isomer of Omeprazole ). 
 
Each molecule had an originator. At different stages in the study time period, 
sales data on one or more generics of the molecule appeared and this data 
extended to the end of the study period. There were only two exceptions to this: 
• Ulsec – Ulsec was taken off the market as it had infringed on the 
originator Losec’s patent. 
• Controloc and Pantoloc – These are identical originator molecules but 
branded differently. 
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There were no generics of Rabeprazole and Esomeprazole launched during the 
period of this study. 
 
 
3.1 A review of launch dates and categorization into molecule class 
 
1) The Medicines Control Council (MCC) website was reviewed to obtain all 
Proton Pump Inhibitors ( PPI)  launched in the last 6 years.  
2) A list of all expired patents from the patents office (Annexure 2) was 
obtained. 
3) All new PPI launched in the last 34 months, specifically August  2003 to 
May 2006 were extracted from IMS. This extract contained the name of the 
product, the date it was launched and the number of months it has been in 
the market (Annexure 3).  
4) The study began with 5 products in August 2003 and the analysis finished in 
May 2006 with 18 products under review. 
5) A comparison on launch dates and registrations was done on the information 
found on the MCC web site, IMS and the patent office to determine the 
exact date when an originator or generic should appear on the data sheet, 
Annexure 6. 
6) All PPI launched were categorized into an appropriate molecule class, see 
table 1.
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Table 1                  PPIs categorized per molecule    
      
      
  Molecules 
Products 
Omeprazol Lansoprazole Pantoprazole Rabeprazole Esomeprazole  
  ULZEC   LANZOR   PANTOLOC   PARIET   NEXIAM 
  LOSEC   LANZOR HB 
  
CONTROLOC     
  OMEZ   ADCO-ROZNAL   TOPZOLE     
  SANDOZ 
OMEPRAZOLE   LANSOLOC       
  ADCO-OMEPRAZOLE 
  ASPEN-
LANSOPRAZOLE       
  ALTOSEC         
  OMILOC         
  NOZER         
  LOSEC MUPS         
 
 
3.2 Extraction of unit sales data on proton pump inhibitors 
 
Retrospective Internal Medical Sales (IMS) data on proton pump inhibitors was 
collected by reviewing and capturing sales data per month over a period of thirty 
four months, from August 2003 to May 2006.  The unit sales data used was the 
moving annual totals (MAT) for each product (Annexure 6).  
 
Sales data was numerical and did not need to be formatted.  The MAT unit sales 
data was tabulated into an electronic file for ease of manipulation.  The reason 
MAT was used instead of monthly unit sales was to reduce the impact of monthly 
variations in sales data. 
 
 
3.3 Allocation of each Proton Pump Inhibitor into either the generisized or non 
generisized group  
 
1) PPI were sorted by using the date of launch as the primary key in ascending 
order. This assisted in determining the originator and the generic/s. 
2) Each PPI was allocated to a group at the start of the study period.  
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3) At the point where a generic of the originator molecule was introduced, the 
originator molecule was moved into the generisized group (Figure 1).   
 
 
 
Figure 1 Maturation of originator molecules by date order 
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3.4 Calculation of average evolution per grouping 
 
Once the product had been allocated to a grouping, the average evolution per 
month in each group was calculated over the thirty four months. This average was 
the simple average of all the EI’s in the group for the month. Only if a product 
appeared for the month in the group would it be used in the calculations. The 
group average per month was entered below the last product in the group 
(Annexure 7). 
 
 
4 Data Analysis 
 
Data Analysis was divided into three parts. 
 
4.1 Descriptive Statistics  
 
(1) Scatter plots were created with moving annual totals (MAT) units of the 
therapeutic class less the generisized molecule on the Y axis and the generisized 
molecule on the X axis at the aggregate level and the molecule specific level. 
Data was plotted for thirty four months and lines of best fit were drawn through 
the data (see also Figures 2 to 12).  A combined graph to determine if there was 
any correlation between the various molecules in the class was also drawn (see 
Figure 4). 
 
(2) Separate graphs of the evolution index of the generic molecule and the 
remainder of the therapeutic class were plotted. Polynomial lines of best fit were 
drawn through this data.  
 
(3) The mean growth and variance of the generisized molecule and the remainder 
of the therapeutic class was calculated. 
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4.2 Measuring Association 
 
Pearson’s correlation coefficient was used to determine correlation and the 
coefficient of determination was calculated to determine goodness of fit for 
Figures 2,5,7,9 and 12 (See Annexure 6 and 7). 
 
 
4.3 Statistical Inference: Hypothesis Testing 
 
Hypothesis  
The launch of generic proton pump inhibitors in South Africa has no effect on 
growth of non generic molecules in the same therapeutic class.  The alternate 
hypothesis is, that the launch of generics, either increases or decreases growth. 
 
The following t-test for two independent means to test the hypothesis was used 
where: 
1.   Ho: µ1 = µ2;  H1: µ1 ≠ µ2 
2.   α = 0.05 
3.   Test statistic:  
 
   T =                      (X1-X2  - (µ1-µ2))                             ~ t(v) 
            √(((n1-1)S12 + (n2-1)S22)/(n1+n2-2))(1/n1+1/ n2) 
 
 
                  n is the population size 
                  S is the sample 
X1 is the mean  EI of generisized molecules 
X2 is the mean EI of non generisized molecules 
 
4.  Reject H0 if t ≤ -2.145 or ≥ 2.145 
 
If the average evolution index of the generisized molecules is significantly greater 
then the non generisized molecules it would imply that there was a growth in the 
generisized molecules and there was not as much increase in the use of alternative 
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drugs in the same therapeutic class. 
 
If, however, there is a statistically significant higher growth in non generisized 
molecules in the same class then the generisized molecule this would imply that 
the impact of the launch results in either therapeutic substitutions or growth in 
molecules other than the generisized molecule. 
 
 
5 Results 
 
5.1 Results of descriptive analysis and measuring association 
 
In order to determine association between generisized and non generisized 
molecules, moving annual totals (MAT) unit sales of the molecules were plotted 
on a scatter graph. This was done for each grouping, aggregate data (Figures 5, 6 
and 7) and then at the molecule specific level (Figures 8, 9 and 10). 
 
5.1.1 Aggregate data  
 
Each point in Figure 2 is the sum of the MAT for a month of generisized 
molecules (x-axis) and the corresponding MAT of the non generisized 
molecules (y-axis). This is done so as to determine the relationship between the 
two MAT over the study period. The points are not in any date order as it is the 
trend of the sum of the two MAT over the study period which is being analyzed.  
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Figure 2 Linear trend between MAT of generisized PPI sold and non 
generisized PPI sold from August 2003 to May 2006 
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The slope of the linear trend line in Figure 2 shows that there may be some 
association between the two groupings although a one to one relationship 
between non generisized molecules and generisized molecules can be ruled out.  
 
A one to one relationship would have meant for every non generisized molecule 
not sold a generisized molecule would take its place and vice a versa.  If there 
was a one to one relationship the slope of the line would have been at 45 
degrees. 
 
Pearson’s correlation coefficient for Figure 2 is -0.83 and the goodness of fit or 
coefficient of determination is 0.69 (Annexure 6).  A correlation of 1 would 
imply there is a direct one to one relation between the two groups.  A negative 
correlation implies that if one group increases the other group decreases.  A 
goodness of fit close to or equal to 1 would have meant that points that make up 
the graph are in close proximity to the trend line which is not the case here. 
Therefore, is it hard to conclude definitively that there is a direct association 
between the two groups. 
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Figure 3  Simultaneous polynomial MAT sales trends of generic and non 
generic molecules from August 2003 to May 2006 
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On plotting the generisized and non generisized data as a stacked graph Figure 3 
and then applying a polynomial trend line it is much easier to pick up visually, 
the inverse symmetry between the generisized molecules and the non 
generisized molecules.  
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Figure 4 MAT unit sales per molecule over thirty four months 
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Figure 4 plots the MAT of the various molecules simultaneously over the study 
period. This is done to check for correlation between the molecules.  There 
appears to be no clear correlation between molecules which implies limited 
therapeutic switching between any two molecules.  
 
Esomeprazole, Omeprazole and Lanzoprazole are growing in MAT unit sales 
whilst Pantaprazole and Rabeprazole appear to be declining slightly. 
 
5.1.2 Molecule specific data 
 
Figures 5, 6 and 7 are based on the same principals as Figure 2, however, the 
data is summarised at the molecule level and not the aggregate level MAT. 
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Figure 5 Linear trend between MAT of the Omeprazole originator - Losec 
and generics of Omeprazole 
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The grouped points on the left in Figure 6 are because Lanzoprazole did not 
have a generic at the beginning of the study period. A generic of Lanzoprazole 
was launched in August 2005. 
 
Figure 6 Linear trend between MAT of the Lanzoprazole originator - Lanzor 
and generic Lanzoprazole sold from August 2003 to May 2006 
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Figure 7 Linear trend between MAT of the Pantoprazole originator - 
Pantoloc (Controloc) and generics of Pantoprazole sold from August 
2003 to May 2006 
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The above Linear trend lines, see Figures 5, 6 and 7, show that there is a 
degree of correlation between the generic and the non generics of the 
molecule as one would expect. 
  
 
However, of the linear trend lines drawn in Figures 5, 6 and 7 between the 
originator and its generics, Omeprazole shows the closest one to one 
association. Therefore it appears from Figure 5 that for Omeprazole, the 
originator was substituted more often by its generic.  
 
Figures 8, 9 and 10 are based on the same principals as Figure 3, however, the 
data is summarised at the molecule level and not the aggregate level MAT 
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Figure 8 Simultaneous polynomial MAT sales trends of the Omeprazole 
originator - Losec and generics of Omeprazole from August 2003 to 
May 2006 
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Figure 9 Simultaneous polynomial MAT sales trends of the Lanzoprazole 
originator - Lanzor and generics of Lanzoprazole from August 2003 
to May 2006 
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Figure 10  Simultaneous polynomial MAT sales trends of the Pantoprazole 
originator and generics of Pantoprazole from August 2003 to May 
2006 
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When stacking the moving annual totals at the molecule level Figures 8, 9 and 
10 over 34 months the symmetry observed at the aggregate level becomes more 
apparent indicating a potential direct correlation. 
 
However, the trend lines in the stacked graph for the generic Omeprazole  
molecules (Figure 8) show that the rate of growth in sales of  generics of 
Omeprazole is greater than the rate of loss of sales of the originator.  
 
 
5.2 Results of descriptive analysis based on evolution indices 
 
In order to determine the growth of the generic molecules, the evolution indices 
(EI) of the molecules were plotted on a scatter graph. This was done at the 
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aggregate or group level. 
 
Each point in Figure 11 is the sum of the EI for a month of generisized molecules 
(x-axis) and the corresponding EI of the non generisized molecules (y-axis).  This 
is done so as to determine the relationship between the two EIs over the study 
period.  The points are not in any date order as it is the trend of the sum of the two 
EIs over the study period which is being analyzed. 
 
A graph of the average evolution indices of the generisized molecule versus non 
generisized molecules to show correlation was constructed. 
 
 
 
Figure 11 Evolution indices of market growth of generisized molecules and 
non generisized molecules plotted to determine correlation for the 
period August 2003 to May 2006 
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Figure 11 shows that one cannot draw a trend line as the points are not grouped 
but scattered. 
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Figure 12 Simultaneous polynomial market growth EI trend lines of 
generisized and non generisized molecules between August 2003 and 
May 2006 
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A polynomial trend line on the stacked data of average evolution indices of 
generic versus non generisized molecules Figure 12 however shows a decrease in 
the average evolution of both the generisized and non generisized molecules 
followed by a growth in their average evolution. 
 
Growth of non-generisized molecules in the first 12 months remains at an average 
EI above 100 and then dips just below 100 as the average EI of generisized 
molecules starts to increase. Around month 22 of the study period the average EI 
of non generisized molecules dips below that of the generisized molecules, which 
coincides with the time when there is a strong growth of Omeprazole generics 
from generic manufacturers Sandoz, Adcock amd Dr. Reddy’s Labs. Also at this 
time Lanzor is generisized taking its considerable volume although low EI into 
the generisized group. These two events bring the average EI’s of the two groups 
closer together and with both EI’s being below 100. However, this is misleading 
as the relationship of the EI  between the two groups i.e. the generised and non 
generisized group is important and not the EI itself of a group as this is only an 
average in the group. 
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5.3 Hypothesis testing 
 
Calculations: Refer to Annexure 7 page 4. 
 
  Test statistic: T =    86.64-97.40-0 
    ---------------------------------------- 
       √ (33x(16.76)2 + 33x(17.28)2) 
    ---------------------------------------- 
                √ 66   
 
     =   - 2.61 
 
 
6 Discussion 
 
 
6.1 Discussion on descriptive analysis and measuring association 
 
At the aggregate level, there is a possibility of a switch  happening from the 
originator molecule to the generisized molecule as the lines mirror each other 
which is what one would have expected see Figure 3. Mandatory substitution  and 
the influence of medical schemes may account for this switch as discussed earlier 
in section 1.4.  
 
Omeprazole in Figure 4 and Figure 8 is particularly interesting as it declines on 
the introduction of generics but has a subsequent sustained increase in growth 
with the highest share in respect of unit sales. This could be as a result of being 
the first molecule to be generisized in the class as well as having the highest 
number of me-too generics in the class. 
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It appears from Figure 4 that Lanzor is a strong brand despite the introduction of 
generics and shows growth in average EI in the last ten months of the study 
period. Interestingly, during this period Lanzor HB a non prescription over the 
counter version of Lanzor was launched. This appears to be a good marketing 
tactic to sustain growth when the class  is being generisized. Marketing practices 
such the launch of a non prescription version of a non generised molecule could  
result in an increase in the utilization of the molecule as the patient would no 
longer need to visit a doctor if not on a medical scheme to obtain a PPI. This 
could result in a net saving to a non medical scheme member.  Although in this 
particular study period there appears to be a switch between the Lanzor and 
Lanzor HB as the combined MAT remains more or less the same. 
 
At the molecule level for Lanzoprazole and Pantarazole, i.e Figures 6 and 7 it 
appears that there is less correlation between the originator and its generics. 
However the slopes of the linear trend lines in Figure 6 and 7 are less than 45° 
which could imply that either both molecules are losing market share or their 
generics are not being accepted as equivalents. 
 
Furthermore, the possibility of Lanzoprazole and Pantaprozole losing market 
share can be reinforced by: 
• The polynomial trend line of the generics of Omeprazole, see Figure 8, 
where the generics appear to be gaining market share. 
• Figure 12 where non generisized molecules appear to have an average EI 
greater than that of generisized molecules. 
 
6.2 Discussion on descriptive analysis based on evolution indices 
 
One would have expected that the generisized molecules would show a consistent 
upward trend in average evolution and the non generisized molecules a consistent 
downward trend.  This expectation is true for the generisized molecules however 
the non generisized molecules also show an upward trend during the latter part of 
the study period (Figure 12).  The significance of this is further tested by way of 
the hypothesis.  
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Since -2.61<-2.145, Ho is rejected and H1 is accepted i.e. the two sample means 
differ significantly, p<0.05.  The mean evolution index is less in generisized 
molecules than with non generisized molecules.  
 
The results of the t-test suggest that even though the volumes of non generisized 
molecules prescribed  reduce, the mean growth of the evolution index of these 
molecules is still greater then that of the generisized molecules.   
 
This is a significant result as it has ramifications on the pharmaceutical industry 
and on medical schemes.  For example, in the pharmaceutical industry, 
manufacturers of original drugs can justify marketing spend in a class that is 
being generisized as long as their particular molecule is patent protected to grow 
market share.  They need not abandon their molecule.  Whilst manufacturers of 
generic drugs need to promote therapeutic switching in addition to generic 
substitution to ensure that market share lost by the originator is not captured by 
non generisized molecules alone. 
 
As for medical schemes, they would need to manage their risk by taking into 
account that their spend on non generisized molecules may increase and offset 
their projected savings from lower priced generics. 
 
 
6.3 Reasons for difference in data and shortcomings  
 
• During the time period from which data has been drawn for this study 
there was a significant change in legislation whereby the price of a 
medicine was fixed in the market making bonusing and discounting illegal 
and at the same time introducing mandatory substitution of generic 
medicines for non generic medicines.  This would explain the poor 
coefficient of determination at the aggregate level on the moving annual 
total graphs Figure 2. 
• IMS data does not take into account what the product is being used for nor 
does it reveal discounting practices or what the cost is to the medical aid 
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or patient. Therefore, there may be other factors determining the growth of 
non generisized molecules as well. 
 
 
6.4 Explanations for the growth of non generisized molecules 
 
Some explanations for growth of non generisized molecules might include: 
 
• Doctors become less likely to prescribe a generisized molecule as they are 
no longer in control of the final brand of generic the patient is dispensed. 
With mandatory substitution the pharmacist is allowed to dispense any 
brand of medicine as long as it is a generic of the same molecule that was 
prescribed by the doctor.  Therefore, a doctor may be more likely to 
prescribe a non generisized molecule to ensure that the patient is 
dispensed the brand the doctor wants. 
 
• Therapeutic switching is more difficult to apply than mandatory 
substitution.  Therapeutic switching occurs when one molecule is 
substituted by another molecule in the same therapeutic class.  Again, a 
doctor in this case would prescribe a non generisized molecule so that his 
script is not changed by either the scheme or the pharmacist unless of 
course it was a ‘breakthrough drug’ which is not the case here. 
 
• Doctors are not convinced of the efficacy and safety of a generic and 
hence will prescribe the originator or non generisized molecule.  A generic 
of a medicine is often perceived as not being as efficacious as the 
originator.  This may be so as doctors, pharmacists and patients do not 
necessarily understand the science behind the development and 
manufacture of a generic.  Another simpler reason why a generic is 
considered inferior could be the perception that a more expensive product 
is better. 
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• Doctors are not sure if the generic product has been manufactured under 
strict manufacturing controls. 
 
• Pharmaceutical companies look at the generisization of a molecule in a 
class as an opportunity to promote their non generisized molecule by 
marketing the integrity of their product. 
 
• Generics are not priced much lower than the originator. Generics in South 
Africa are generally priced at a discount of between 20% to 30% lower 
than the price of the originator.  Often this price differential is met by an 
out of pocket expense of the patient.  It could also be that there is a 
resentment that generics are not priced at a much lower cost and therefore 
mandatory substitution is not enforced. 
 
• Generics are costly.  The Canadian experience 10 suggested that me-too 
generics increased the price of a generisized molecule.  This phenomenon 
may be due to that after the launch of multiple generics over a period of 
time one may forget the originator and its price.  Once this happens the 
individual is more likely to accept a price that increases regularly with 
inflation regardless of the fact that the API may have become cheaper and 
the manufacturing efficiency gains could be greater then inflation. 
Additionally, in South Africa as more me-too generics are launched 
manufacturers of generic medicines have adopted a strategy to brand their 
generics.  Branded generics require promotional spend which in turns 
contributes to the maintenance of higher prices. 
 
• There is a perception that a generisized drug is old technology regardless 
of when the patent was actually filed of the originator molecule.  A newer 
molecule could have been bought into South Africa and started its period 
of exclusivity whilst an older molecule could have been brought later into 
South Africa and would enjoy exclusivity beyond the patent expiry of the 
newer molecule. 
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6.5 Further studies 
 
To complement and develop this study, further work to understand growth the in 
non generisized molecules may include: 
• What happens to the price of the originator once a generic of itself has 
been launched? 
• At what price is a generic launched?  
• What would be the conclusion if this methodology was applied across all 
therapeutic classes in one study 
• What would be the conclusion if the study was repeated with medical 
schemes claims data. 
 
 
7 Conclusion 
 
The results of this research topic highlight that non generisized molecules in a 
therapeutic class do not necessarily stop being prescribed.  Data in Annexure 7 
and the pursuant testing of the hypothesis suggests that their use increases at a 
faster pace that the generisized molecules. 
 
This research disproves the hypothesis that mean growth in generic molecules is 
equal to non generisized molecules and proves that the mean evolution index is 
less in generisized molecules than in non generisized molecules. 
 
This finding is unexpected. One would have assumed that with therapeutic 
substitution, formularies and co-payments the growth of the non generisized 
molecules would have been reduced.  
 
To apply the findings of this research generally would be premature as each 
therapeutic class would have its own characteristics.  
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 Annexures 
 
Annexure 1 
IMS data sample sheet 
 
 
Annexure 2 
Basic Pharmaceutical Patents in South Africa which expire in 2000 onwards. 
Specifically, Proton Pump Inhibitors. 
 
Pharmaceutical Patent Patent number Date of expiry 
Omeprazole process 83/5143 14.07.2003 
Omeprazole salts 84/1202 17.02.2004 
Omeprazole composition 87/2378 01.04.2007 
Omeprazole composition with antibiotic 93/2364 01.04.2013 
Omeprazole crystalline form 98/11174 07.12.2018 
Pantoprazole 85/4287 06.06.2005 
   
   
 
New Proton Pump Inhibitors launched between October 2003 and September 2005
Product Date Launched 
ADCO-OMEPRAZOLE September-04
SANDOZ OMEPRAZOLE August-04
ALTOSEC January-05
OMEZ July-04
LANZOR HB April-04
OMILOC January-05
LANSOLOC August-05
ADCO-ROZNAL August-05
NOZER October-06
ASPEN-LANZOPRAZOLE November-06
TOPOZOLE January-06
Annexure 3
 
Annexure 4 
 
Opinion on suitability of statistical method 
 
 
 
ClinStat CC 
Reg No CK 96/35541/23 
 
250 PEERBOOM STREET 
DOORNPOORT  
PRETORIA 
0017 
P O BOX 14835 
SINOVILLE 
PRETORIA 
0129 
 
e-mail: clinstat@telkomsa.net             Tel:  012 547 7068 
Fax:  012 547 1571 
       Cell:  082 896 3606 
______________________________________________________________________________________ 
 
 
 
Dear Mr Mangalmurti, 
  
This is to confirm that I reviewed your Research Protocol entitled "A retrospective 
analysis of the unit growth of non-generisized proton pump inhibitors after the 
launch of generic molecules in the therapeutic class".   
 
The t test that you propose is a suitable test for the comparison of two mean 
values from two independent samples, and would be applicable at each of the 
time points of your dataset. I am also investigating other possible statistical 
techniques for the comparison of the two groups over time, and will communicate 
with you later in this regard. 
 
Yours sincerely, 
 
 
Prof HS Schoeman 
Biostatistician 
 
22 February 2006 
 
Annexure 5 
 
 
Ethics approval 
 
 
Annexure 6 Raw data on moving annual totals and calculation of Pearsons correlation coefficient and coefficient of determination
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TC IV DESC MAT ~ 08/2003 MAT ~ 09/2003 MAT ~ 10/2003 MAT ~ 11/2003 MAT ~ 12/2003 MAT ~ 01/2004 MAT ~ 02/2004 MAT ~ 03/2004
         
Non generisized
l   LANZOR             S.A 300,606 302,207 304,852 309,257 309,621 309,438 315,733 318,932
e   NEXIAM             AZN 204,101 213,232 220,101 228,107 236,641 242,824 250,577 258,323
p   PANTOLOC           AMU 136,035 142,648 147,600 155,475 163,827 169,633 177,612 184,815
r   PARIET             JAN 91,579 92,872 93,081 93,513 94,613 94,348 95,029 95,570
p   CONTROLOC          AMU 55,441 57,363 59,116 61,033 62,718 64,819 67,077 69,501
l   LANZOR HB          S.A 0 0 0 0 0 0 0 0
Total non generisized 787,762 808,322 824,750 847,385 867,420 881,062 906,028 927,141
Generisized
o   ULZEC              TR/ 66,949 55,611 42,998 35,729 27,841 20,045 6,866 1,736
o   LOSEC              AZN 66,465 76,821 75,669 75,528 73,911 74,287 73,472 73,485
o   OMEZ               DRL 0 0 0 0 0 0 0 0
o   SANDOZ OMEPRAZOLE  SDZ 0 0 0 0 0 0 0 0
o   ADCO-OMEPRAZOLE    AOJ 0 0 0 0 0 1 1 1
o   ALTOSEC            A&G 0 0 0 0 0 0 0 0
o   OMILOC             HEX 0 0 0 0 0 0 0 0
l   ADCO-ROZNAL        AOJ 0 0 0 0 0 0 0 0
l   LANSOLOC           CD8 0 0 0 0 0 0 0 0
o   NOZER              BE- 0 0 0 0 0 0 0 0
l   ASPEN-LANSOPRAZOLE A&G 0 0 0 0 0 0 0 0
p   TOPZOLE            AOJ 0 0 0 0 0 0 0 0
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN 156,605 156,390 155,732 155,937 155,972 155,287 158,196 158,910
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TC IV DESC
 
Non generisized
l   LANZOR             S.A
e   NEXIAM             AZN
p   PANTOLOC           AMU
r   PARIET             JAN
p   CONTROLOC          AMU
l   LANZOR HB          S.A
Total non generisized
Generisized
o   ULZEC              TR/
o   LOSEC              AZN
o   OMEZ               DRL
o   SANDOZ OMEPRAZOLE  SDZ
o   ADCO-OMEPRAZOLE    AOJ
o   ALTOSEC            A&G
o   OMILOC             HEX
l   ADCO-ROZNAL        AOJ
l   LANSOLOC           CD8
o   NOZER              BE-
l   ASPEN-LANSOPRAZOLE A&G
p   TOPZOLE            AOJ
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN
MAT ~ 04/2004 MAT ~ 05/2004 MAT ~ 06/2004 MAT ~ 07/2004 MAT ~ 08/2004 MAT ~ 09/2004 MAT ~ 10/2004 MAT ~ 11/2004
        
309,321 304,508 295,059 288,739 289,507 283,994 279,644 271,651
260,818 269,938 276,855 282,966 294,183 300,678 310,234 319,427
189,102 198,642 202,175 205,429 212,461 216,460 221,316 226,076
94,584 94,656 94,354 94,032 93,136 91,261 90,834 90,129
70,558 72,027 72,523 72,458 73,139 73,424 74,174 74,773
0 1,627 4,004 6,910 12,151 17,140 21,793 26,760
924,383 941,398 944,970 950,534 974,577 982,957 997,995 1,008,816
265 119 91 78 50 42 38 20
72,206 74,020 72,465 71,416 71,222 67,596 69,942 72,464
0 0 0 0 1,317 2,936 5,111 7,772
0 0 0 0 2,731 5,580 9,545 14,697
1 1 1 1 1 2,091 5,236 10,891
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
155,442 155,260 153,395 150,743 150,474 147,861 145,470 143,061
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TC IV DESC
 
Non generisized
l   LANZOR             S.A
e   NEXIAM             AZN
p   PANTOLOC           AMU
r   PARIET             JAN
p   CONTROLOC          AMU
l   LANZOR HB          S.A
Total non generisized
Generisized
o   ULZEC              TR/
o   LOSEC              AZN
o   OMEZ               DRL
o   SANDOZ OMEPRAZOLE  SDZ
o   ADCO-OMEPRAZOLE    AOJ
o   ALTOSEC            A&G
o   OMILOC             HEX
l   ADCO-ROZNAL        AOJ
l   LANSOLOC           CD8
o   NOZER              BE-
l   ASPEN-LANSOPRAZOLE A&G
p   TOPZOLE            AOJ
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN
MAT ~ 12/2004 MAT ~ 01/2005 MAT ~ 02/2005 MAT ~ 03/2005 MAT ~ 04/2005 MAT ~ 05/2005 MAT ~ 06/2005 MAT ~ 07/2005
        
268,336 265,806 255,743 249,204 245,022 242,083 239,438 236,919
327,763 337,081 345,120 352,273 363,176 371,911 379,967 388,490
230,182 235,878 240,855 243,527 248,204 248,315 253,009 254,321
88,512 87,979 86,706 84,941 84,990 84,170 82,667 81,375
75,903 76,210 75,888 75,710 76,485 76,682 75,982 76,092
31,976 35,999 40,386 45,873 51,232 55,181 60,118 63,075
1,022,672 1,038,953 1,044,698 1,051,528 1,069,109 1,078,342 1,091,181 1,100,272
12 5 3 3 3 0 0 0
72,990 74,182 76,685 78,744 82,378 83,772 86,242 84,551
10,777 14,556 18,148 21,716 25,602 29,188 32,830 36,392
18,690 22,260 26,578 30,917 36,898 43,083 51,610 62,514
17,398 28,316 38,699 48,265 59,179 70,431 80,348 84,011
0 3,057 7,877 13,047 18,503 22,977 29,243 35,552
0 0 1,143 2,682 5,320 8,687 12,199 16,022
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
138,894 136,263 129,530 124,371 120,526 116,414 111,554 107,183
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TC IV DESC
 
Non generisized
l   LANZOR             S.A
e   NEXIAM             AZN
p   PANTOLOC           AMU
r   PARIET             JAN
p   CONTROLOC          AMU
l   LANZOR HB          S.A
Total non generisized
Generisized
o   ULZEC              TR/
o   LOSEC              AZN
o   OMEZ               DRL
o   SANDOZ OMEPRAZOLE  SDZ
o   ADCO-OMEPRAZOLE    AOJ
o   ALTOSEC            A&G
o   OMILOC             HEX
l   ADCO-ROZNAL        AOJ
l   LANSOLOC           CD8
o   NOZER              BE-
l   ASPEN-LANSOPRAZOLE A&G
p   TOPZOLE            AOJ
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN
MAT ~ 08/2005 MAT ~ 09/2005 MAT ~ 10/2005 MAT ~ 11/2005 MAT ~ 12/2005 MAT ~ 01/2006 MAT ~ 02/2006 MAT ~ 03/2006
        
394,356 402,122 412,558 421,376 432,830 441,879 453,781 461,705
252,822 253,522 252,997 252,060 250,115
80,347 79,919 79,069 77,646 77,710 76,740 75,316 74,299
75,581 74,768 74,108 72,985 72,286
803,106 810,331 818,732 824,067 832,941 518,619 529,097 536,004
0 0 0 0 0 0 0 0
81,109 77,538 75,902 70,367 64,942 60,532 55,176 49,159
39,076 41,018 42,608 44,212 45,652 46,251 47,026 47,372
73,300 80,191 86,605 88,519 91,301 94,042 95,027 97,879
95,926 100,759 104,992 109,889 118,183 118,873 120,923 124,550
43,952 51,862 60,990 72,860 88,440 103,675 118,529 127,478
20,589 24,386 26,746 26,842 26,848 26,860 26,943 26,855
1,522 2,697 4,187 5,437 6,622 9,416 10,639 12,491
7,126 16,315 28,768 46,024 66,033 86,117 109,171 132,511
5 5 5 789 1,502 2,346 3,366 3,874
0 0 0 727 1,479 2,906 4,884 5,840
0 0 0 0 0 1,726 4,259 7,178
231,564 225,314 215,266 204,393 192,191 179,798 166,879 154,735
63,747 64,263 63,224 62,228 59,799 57,610 56,012 53,153
249,135 245,887 243,402
71,363 69,791 67,797
101,849 98,498 95,715 92,761 90,705 88,149 86,196 84,086
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TC IV DESC
 
Non generisized
l   LANZOR             S.A
e   NEXIAM             AZN
p   PANTOLOC           AMU
r   PARIET             JAN
p   CONTROLOC          AMU
l   LANZOR HB          S.A
Total non generisized
Generisized
o   ULZEC              TR/
o   LOSEC              AZN
o   OMEZ               DRL
o   SANDOZ OMEPRAZOLE  SDZ
o   ADCO-OMEPRAZOLE    AOJ
o   ALTOSEC            A&G
o   OMILOC             HEX
l   ADCO-ROZNAL        AOJ
l   LANSOLOC           CD8
o   NOZER              BE-
l   ASPEN-LANSOPRAZOLE A&G
p   TOPZOLE            AOJ
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN
MAT ~ 04/2006 MAT ~ 05/2006
  
473,567 484,786
73,568 72,582
547,135 557,368
0 0
42,258 36,128
47,861 48,257
99,399 100,527
125,689 124,910
150,485 167,031
25,689 23,863
13,826 15,187
157,522 183,085
4,406 7,081
7,805 9,742
10,284 14,027
142,134 129,916
50,352 46,982
240,565 236,668
65,305 62,576
81,611 79,221
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1 2 3 4 5 6 7 8
Total generisized 290,019 288,822 274,399 267,194 257,724 249,620 238,535 234,132
Total non generisized 787,762 808322 824750 847385 867420 881062 906028 927141
1,077,781 1,097,144 1,099,149 1,114,579 1,125,144 1,130,682 1,144,563 1,161,273
Omeprazole 66,949 55,611 42,998 35,729 27,841 20,046 6,867 1,737
Originator 223,070 233,211 231,401 231,465 229,883 229,574 231,668 232,395
Lansoprazole 0 0 0 0 0 0 0 0
Originator 300,606 302,207 304,852 309,257 309,621 309,438 315,733 318,932
Pantoprazole
Originator 191,476 200,011 206,716 216,508 226,545 234,452 244,689 254,316
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Total generisized
Total non generisized
Omeprazole
Originator
Lansoprazole
Originator
Pantoprazole
Originator
9 10 11 12 13 14 15 16
227,914 229,400 225,952 222,238 225,795 226,106 235,342 248,905
924383 941398 944970 950534 974577 982957 997995 1008816
1,152,297 1,170,798 1,170,922 1,172,772 1,200,372 1,209,063 1,233,337 1,257,721
266 120 92 79 4,099 10,649 19,930 33,380
227,648 229,280 225,860 222,159 221,696 215,457 215,412 215,525
0 0 0 0 0 0 0 0
309,321 306,135 299,063 295,649 301,658 301,134 301,437 298,411
259,660 270,669 274,698 277,887 285,600 289,884 295,490 300,849
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Total generisized
Total non generisized
Omeprazole
Originator
Lansoprazole
Originator
Pantoprazole
Originator
17 18 19 20 21 22 23 24
258,761 278,639 298,663 319,745 348,409 374,552 404,026 426,225
1022672 1038953 1044698 1051528 1069109 1078342 1091181 1100272
1,281,433 1,317,592 1,343,361 1,371,273 1,417,518 1,452,894 1,495,207 1,526,497
46,877 68,194 92,448 116,630 145,505 174,366 206,230 234,491
211,884 210,445 206,215 203,115 202,904 200,186 197,796 191,734
0 0 0 0 0 0 0 0
300,312 301,805 296,129 295,077 296,254 297,264 299,556 299,994
306,085 312,088 316,743 319,237 324,689 324,997 328,991 330,413
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Total generisized
Total non generisized
Omeprazole
Originator
Lansoprazole
Originator
Pantoprazole
Originator
25 26 27 28 29 30 31 32
759,765 782,846 805,008 825,048 853,697 1,198,799 1,220,708 1,238,360
803106 810331 818732 824067 832941 518619 529097 536004
1,562,871 1,593,177 1,623,740 1,649,115 1,686,638 1,717,418 1,749,805 1,774,364
272,848 298,221 321,946 343,111 371,926 392,047 411,814 428,008
182,958 176,036 171,617 163,128 155,647 148,681 141,372 133,245
8,648 19,012 32,955 52,188 74,134 98,439 124,694 150,842
295,311 289,577 278,490 266,621 251,990 237,408 222,891 207,888
1,726 4,259 7,178
328,403 328,290 327,105 325,045 322,401 320,498 315,678 311,199
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Total generisized
Total non generisized
Omeprazole
Originator
Lansoprazole
Originator
Pantoprazole
Originator
33 34
1,265,191 1,285,201
547135 557368
1,812,326 1,842,569
453,529 471,669
123,869 115,349
179,153 208,014
192,486 176,898
10,284 14,027
305,870 299,244
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Pearson 
correlation 
coefficient
Coefficient of 
determination 
(goodness of 
fit)
Total generisized -0.831633 0.691613
Omeprazole -0.973349 0.947407
Lansoprazole -0.988142 0.976424
Pantoprazole -0.999645 0.999291
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 ACID PUMP INHIBITORS Aug-03 Sep-03 Oct-03 Nov-03 Dec-03 Jan-04 Feb-04 Mar-04 Apr-04
Non generisized
l   LANZOR             S.A 63.32 86.43 109.63 100.14 90.79 92.93 110.44 95.78 77.94
  NEXIAM             AZN 155.84 135.93 147.42 130.48 141.65 134.51 126.21 122.31 122.82
p   PANTOLOC           AMU 156.13 139.66 144.06 161.01 170.50 160.57 159.37 137.99 145.70
  PARIET             JAN 101.71 95.24 100.72 89.21 102.67 90.25 95.06 89.76 96.44
p   CONTROLOC          AMU 152.41 119.40 141.55 125.34 128.16 145.94 133.71 135.27 133.47
l   LANZOR HB          S.A 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average evolution - non generisized 125.88 115.33 128.68 121.24 126.75 124.84 124.96 116.22 115.27
Generisized
o   ULZEC              TR/ 0.36 0.06 0.03 0.21 0.09 0.08 0.01 0.00 0.00
o   LOSEC              AZN 0.00 0.00 78.25 81.84 71.25 102.31 75.19 83.97 86.36
o   OMEZ               DRL 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
o   SANDOZ OMEPRAZOLE  SDZ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
o   ADCO-OMEPRAZOLE    AOJ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
o   ALTOSEC            A&G 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
o   OMILOC             HEX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
l   ADCO-ROZNAL        AOJ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
l   LANSOLOC           CD8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
o   NOZER              BE- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
l   ASPEN-LANSOPRAZOLE A&G 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
p   TOPZOLE            AOJ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
l   LANZOR             S.A
l   LANZOR HB          S.A
p   PANTOLOC           AMU
p   CONTROLOC          AMU
o   LOSEC MUPS         AZN 91.52 79.60 92.98 85.70 89.67 88.41 108.42 88.71 85.30
Average evolution - generisized 91.52 79.6 85.615 83.77 80.46 95.36 91.805 86.34 85.83
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 ACID PUMP INHIBITORS
Non generisized
  LANZOR             S.A
  NEXIAM             AZN
  PANTOLOC           AMU
  PARIET             JAN
  CONTROLOC          AMU
  LANZOR HB          S.A
Average evolution - non generisized
Generisized
  ULZEC              TR/
  LOSEC              AZN
  OMEZ               DRL
  SANDOZ OMEPRAZOLE  SDZ
  ADCO-OMEPRAZOLE    AOJ
  ALTOSEC            A&G
  OMILOC             HEX
  ADCO-ROZNAL        AOJ
  LANSOLOC           CD8
  NOZER              BE-
  ASPEN-LANSOPRAZOLE A&G
  TOPZOLE            AOJ
  LANZOR             S.A
  LANZOR HB          S.A
  PANTOLOC           AMU
  CONTROLOC          AMU
  LOSEC MUPS         AZN
Average evolution - generisized
May-04 Jun-04 Jul-04 Aug-04 Sep-04 Oct-04 Nov-04 Dec-04 Jan-05 Feb-05 Mar-05 Apr-05 May-05
67.52 69.81 74.35 79.66 72.13 65.12 57.02 69.89 62.41 53.71 58.44 55.18 64.60
127.10 133.13 128.47 118.44 118.74 116.07 112.71 109.91 102.52 106.57 101.37 98.28 99.80
146.94 123.64 120.02 113.93 115.65 103.95 103.20 99.70 99.09 103.54 89.97 85.16 75.04
83.23 96.45 93.96 69.13 72.17 74.49 72.82 65.51 64.96 68.44 61.49 67.57 66.40
106.61 108.09 97.16 85.84 96.62 89.52 88.32 97.18 74.03 76.76 76.34 75.85 76.93
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 255.87
106.28 106.22 102.79 93.40 95.06 89.83 86.81 88.44 80.60 81.80 77.52 76.41 106.44
1.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
111.09 78.64 82.91 74.70 59.93 119.43 122.05 87.52 89.15 120.70 105.37 118.76 89.47
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
81.21 87.10 79.68 75.31 73.00 64.02 64.04 55.99 54.22 44.35 47.07 45.77 49.49
96.15 82.87 81.3 75.005 66.465 91.73 93.05 71.755 71.69 82.525 76.22 82.27 69.48
Annexure 7 Raw data on evolution indices and calculation of Pearsons correlation coefficient and coefficient of determination
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 ACID PUMP INHIBITORS
Non generisized
  LANZOR             S.A
  NEXIAM             AZN
  PANTOLOC           AMU
  PARIET             JAN
  CONTROLOC          AMU
  LANZOR HB          S.A
Average evolution - non generisized
Generisized
  ULZEC              TR/
  LOSEC              AZN
  OMEZ               DRL
  SANDOZ OMEPRAZOLE  SDZ
  ADCO-OMEPRAZOLE    AOJ
  ALTOSEC            A&G
  OMILOC             HEX
  ADCO-ROZNAL        AOJ
  LANSOLOC           CD8
  NOZER              BE-
  ASPEN-LANSOPRAZOLE A&G
  TOPZOLE            AOJ
  LANZOR             S.A
  LANZOR HB          S.A
  PANTOLOC           AMU
  CONTROLOC          AMU
  LOSEC MUPS         AZN
Average evolution - generisized
Jun-05 Jul-05 Aug-05 Sep-05 Oct-05 Nov-05 Dec-05 Jan-06 Feb-06 Mar-06 Apr-06 May-06
Pearson 
correlation 
coefficient
62.36 65.77
91.49 100.17 90.58 99.31 106.49 105.70 104.49 104.13 109.33 105.08 105.90 108.78
88.94 80.96 71.26 81.15 76.95 79.10 69.75
57.62 61.51 66.63 73.40 69.30 66.02 77.33 67.75 64.26 70.66 70.72 69.89
63.56 76.92 70.60 68.19 70.89 68.32 68.64
218.39 152.22
97.06 89.59 74.77 80.51 80.91 79.79 80.05 85.94 86.80 87.87 88.31 89.34 -0.1521488
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
101.74 52.90 35.80 36.79 60.39 20.34 16.03 17.54 23.49 21.49 13.70 22.37
0.00 0.00 232.58 172.38 136.75 132.62 113.34 92.46 97.83 92.25 88.64 91.27
0.00 0.00 378.92 267.94 206.79 113.48 130.01 141.09 98.83 139.36 98.74 97.18
0.00 0.00 0.00 259.61 185.33 154.39 174.29 84.85 96.36 115.97 86.95 76.50
0.00 0.00 0.00 0.00 0.00 0.00 0.00 477.55 328.46 229.65 410.73 386.16
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 86.31 79.28 43.93 37.62
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
58.34 53.64 39.86 37.16 32.55 30.10 28.44 30.41 27.48 28.98
86.37 86.48 61.36 66.15 40.94 36.38 51.16 40.28 37.58 32.52
75.83 68.92 74.15 68.61 67.52
67.88 60.01 57.01 49.56 48.56
43.39 46.42 43.53 51.92 57.36 57.28 59.86 56.74 61.31 61.11 55.11 57.89
72.57 49.66 139.26 132.68 106.8 83.06 81.003 108 91.011 85.542 89.18 86.052
Annexure 7 Raw data on evolution indices and calculation of Pearsons correlation coefficient and coefficient of determination
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 ACID PUMP INHIBITORS
Non generisized
  LANZOR             S.A
  NEXIAM             AZN
  PANTOLOC           AMU
  PARIET             JAN
  CONTROLOC          AMU
  LANZOR HB          S.A
Average evolution - non generisized
Generisized
  ULZEC              TR/
  LOSEC              AZN
  OMEZ               DRL
  SANDOZ OMEPRAZOLE  SDZ
  ADCO-OMEPRAZOLE    AOJ
  ALTOSEC            A&G
  OMILOC             HEX
  ADCO-ROZNAL        AOJ
  LANSOLOC           CD8
  NOZER              BE-
  ASPEN-LANSOPRAZOLE A&G
  TOPZOLE            AOJ
  LANZOR             S.A
  LANZOR HB          S.A
  PANTOLOC           AMU
  CONTROLOC          AMU
  LOSEC MUPS         AZN
Average evolution - generisized
Coefficient of 
determination 
( goodness of 
fit )
0.023149
Annexure 7 Raw data on evolution indices and calculation of Pearsons correlation coefficient and coefficient of determination
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Time period 1 2 3 4 5 6 7 8 9
Average evolution - generisized 91.52 79.60 85.62 83.77 80.46 95.36 91.81 86.34 85.83
Average evolution - non generisized 125.882 115.332 128.676 121.236 126.754 124.84 124.958 116.222 115.274
Hypothesis testing
Sample size
Sample 
mean
Sample 
variance
34 86.64 16.735516
34 97.40 17.277431
T statistic 4.1251992
-10.77
-2.609797
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Time period
Average evolution - generisized
Average evolution - non generisized
10 11 12 13 14 15 16 17 18 19 20 21 22
96.15 82.87 81.30 75.01 66.47 91.73 93.05 71.76 71.69 82.53 76.22 82.27 69.48
106.28 106.224 102.8 93.4 95.062 89.83 86.81 88.438 80.6 81.804 77.522 76.41 106.44
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Time period
Average evolution - generisized
Average evolution - non generisized
23 24 25 26 27 28 29 30 31 32 33 34
72.57 49.66 139.26 132.68 106.83 83.06 81.00 108.04 91.01 85.54 89.18 86.05
97.06 89.59 74.768 80.513 80.91 79.79 80.053 85.94 86.795 87.87 88.31 89.335
Annexure 7 Raw data on evolution indices and calculation of Pearsons correlation coefficient and coefficient of determination
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Time period
Average evolution - generisized
Average evolution - non generisized
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Annexure 7 Raw data on evolution indices and calculation of Pearsons correlation coefficient and coefficient of determination
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Hypothesis testing
Sample size Sample mean Sample variance
34 86.64 16.7355
34 97.40 17.2774
T statistic 4.1252
-10.77
-2.6098
